NancyAnnDawsonMD
Oncology • Washington, DCGenitourinary Oncology, Hematologic Oncology
Professor of Medicine, Georgetown University
Dr. Dawson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3800 Reservoir Rd NW
Washington, DC 20007Phone+1 202-444-2223Fax+1 202-444-9429
Education & Training
National Capital ConsortiumFellowship, Hematology and Medical Oncology, 1982 - 1985- National Capital ConsortiumResidency, Internal Medicine, 1979 - 1982
Georgetown University School of MedicineClass of 1979
Certifications & Licensure
MD State Medical License 1984 - 2026
DC State Medical License 2007 - 2024
VA State Medical License 1988 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer Start of enrollment: 1996 Oct 01
- S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer Start of enrollment: 1999 Oct 15
- ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer Start of enrollment: 2001 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 2628 citationsAtezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-a...Jonathan E. Rosenberg, Jean H. Hoffman-Censits, Thomas Powles, Michiel S. van der Heijden, Arjun Vasant Balar
Lancet. 2016-05-07 - 1467 citationsAtezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg, Thomas Powles, Daniel P. Petrylak
Lancet. 2017-01-07 - 61 citationsA randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181.Nancy A. Dawson, Mark R. Conaway, Susan Halabi, Eric P. Winer, Eric J. Small
Cancer. 2000-02-15
Other
- Castrate resistant prostate cancer: Treatments targeting the androgen pathwayDawson NA, Ryan CJ
http://www.uptodate.com/contents/castrate-resistant-prostate-cancer-treatments-targeting-the-androge
UpToDate, Wolters Kluwer Health - 2013-02-21 - Chemotherapy in castrate-resistant prostate cancerDawson NA, Hussain A
http://www.uptodate.com/contents/chemotherapy-in-castrate-resistant-prostate-cancer
UpToDate, Wolters Kluwer Health - 2013-01-21 - Overview of the treatment of disseminated prostate cancerDawson NA
http://www.uptodate.com/contents/overview-of-the-treatment-of-disseminated-prostate-cancer
UpToDate, Wolters Kluwer Health - 2013-04-09 - Join now to see all
Press Mentions
Data May Support Routine Tumor Testing for HRR Gene Alterations in mCRPCOctober 15th, 2019
Clinical Trials: Doctors Want Participation and Bioethicists Warn Against Unrealistic ExpectationsMay 29th, 2018
Grant Support
- Cancer And Leukemia Group BNational Cancer Institute1995–1998
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
